| 1 |
STRONG
|
82
|
NEUTRAL
|
web_search |
The US and China have reached a series of tariff truces in 2025 (90-day reductions, extended through November 2026), plus the 'Busan Deal' in October 2025 covering fentanyl precursors, rare earths, and agricultural purchases — but none of these constitute a formal free trade agreement. |
Yes |
| 2 |
MODERATE
|
75
|
↓ DOWN
|
web_search |
Trump visited China from March 31–April 2, 2026 for a summit with Xi; deliverables were expected to be narrow (commercial purchases like soybeans), framing the meeting as the opening of a longer conversation rather than a breakthrough deal. |
Yes |
| 3 |
STRONG
|
80
|
↓ DOWN
|
web_search |
Even after the Supreme Court's February 2026 IEEPA ruling, US tariffs on China still average nearly 30%, up from ~21% when Trump took office, indicating no comprehensive trade liberalization. |
Yes |
| 4 |
STRONG
|
85
|
↓ DOWN
|
wikipedia_lookup |
The US-China Phase 1 deal (2020) was explicitly NOT a free trade agreement, and the ongoing trade war dating from 2018 remains largely unresolved with major structural disputes over IP, technology transfer, and market access. |
Yes |
| 5 |
MODERATE
|
55
|
↑ UP
|
kalshi_data |
The directly relevant Kalshi market (KXFTAPRC-29) prices the US-China FTA with China at 37%, up +4% in 7 days but down -3% over 30 days, with a historical range of 15–68%. |
Yes |
| 6 |
STRONG
|
82
|
↓ DOWN
|
web_search |
All agreements reached between the US and China since 2025 have been narrow tariff truces or purchase commitments (soybeans, fentanyl, rare earths), none approaching the comprehensive scope (goods, services, IP, investment) required to qualify as a free trade agreement. |
Yes |
| 7 |
STRONG
|
88
|
↓ DOWN
|
wikipedia_lookup |
All 14+ US FTAs have been with smaller trade partners (Canada, Mexico, Australia, South Korea, etc.); the US has never negotiated an FTA with a major strategic competitor, and the US-China relationship is categorically more complex than any prior FTA negotiation. |
Yes |
| 8 |
STRONG
|
88
|
↓ DOWN
|
wikipedia_lookup |
USMCA — a renegotiation of an existing FTA with close allies — took roughly 3 years from initiation to ratification (2017–2020); a new US-China FTA from scratch would likely require significantly longer. |
Yes |
| 9 |
MODERATE
|
75
|
↓ DOWN
|
web_search |
The April 2026 Trump-Xi summit in China was expected to narrow toward commercial purchases rather than any 'grand bargain,' with no indication either side is pursuing FTA-level negotiations. |
No |
| 10 |
MODERATE
|
70
|
↓ DOWN
|
web_search |
Congressional appetite for a US-China FTA is extremely low given bipartisan hawkishness on China; no legislative movement toward granting fast-track authority for US-China trade negotiations has been reported. |
Yes |
| 11 |
STRONG
|
88
|
↓ DOWN
|
wikipedia_lookup |
FTA ratification requires congressional action; USMCA ratification took over a year from signing to final ratification, even with bipartisan support and existing NAFTA precedent. |
Yes |
| 12 |
WEAK
|
35
|
↓ DOWN
|
code_execution |
A conditional probability model estimates the combined probability of (1) any deal, (2) FTA scope, and (3) congressional ratification at ~0.6%, based on input assumptions of 15% for any deal, 10% FTA scope given a deal, and 40% ratification given FTA scope. |
No |
| 13 |
MODERATE
|
52
|
↓ DOWN
|
kalshi_data |
The general 'Trump makes a new FTA before 2029' market (KXFTA-29, not China-specific) is priced at 47%, down -13% over 30 days; the China-specific FTA market is lower at 37%, suggesting markets see China as harder than other potential FTA partners. |
Yes |
| 14 |
MODERATE
|
78
|
NEUTRAL
|
web_search |
The Supreme Court ruled in February 2026 that the President cannot use IEEPA to impose tariffs, constraining the executive's unilateral tariff toolkit and potentially shifting more trade authority back toward Congress. |
Yes |